

# 10<sup>th</sup> Global Annual Oncologists Meeting

July 11-13, 2016 Cologne, Germany



## Martin Burow

DMB-Diagnostics GmbH, Germany

### New method of quantitative, circulating tumor cell (CTC) diagnostic, treatment selection, monitoring and surveillance with superior outcome for the patient

Maintrac® is a laboratory based method to quantify in a reproducible manner living circulating tumor cells. This way it is possible to do further analytic with these cells. Be it molecular genetic testing of certain tumor characteristics or surface protein determination for real pharmaceutical target identification. Since these CTCs are alive, it is possible to check all different chemotherapeutics and their killing rate on these CTCs. Best working medications can be selected before starting aggressive chemotherapies. Furthermore, it is possible to monitor treatment success “just” by quantifying CTC over the course of the therapy. Even during and after endocrine therapy, it is possible to show how long to give i.e., Tamoxifen or when to switch to other, more efficient medication in case the cell number is increasing. This method was developed over the last decade and work on all tumors deriving from epithelial origin (almost all solid tumors). We showed in several clinical trials with >650 patients and >100,000 measurement significant improvement for patients and the overall relapse free survival while being monitored with this method. Maintrac® is nowadays already used in clinical routine in ~30 countries worldwide.

### Biography

Martin Burow has completed his PhD in Chemistry and Biochemistry at the University of Münster in 1993 and worked 3 years as a Post-doctoral fellow for the Ministry of International Trade and Industry at the National Institute of Materials and Chemical Research (NIMC) in Tsukuba, Japan. After his return to Germany, he started his career in the medical device industry and developed the Asian-Pacific markets for Brahms-ThermoFisher in the field of medical diagnostics (thyroid, sepsis, prenatal and oncology). Later, he started his own company (DMB-Diagnostics GmbH) to introduce highly innovative diagnostics worldwide for better treatment standards for oncological patients.

[info@dmb-diagnostics.de](mailto:info@dmb-diagnostics.de)

### Notes: